SHR 0302 is an innovative JAK1 inhibitor with high selectivity. Reistone is currently carrying out global multi-center clinical programs of SHR 0302, in both oral and topical dosage forms, for Inflammatory Bowel Diseases (IBD) such as Ulcerative colitis (UC) and Crohn‘s disease (CD), as well as inflammatory skin diseases such as Atopic Dermatitis, Alopecia Areata and Vitiligo.
Study 1: RSJ10101 a Phase II in subjects with moderate to severe active Ulcerative Colitis NCT03675477
Study 2: RSJ10201 a Phase II in subjects with moderate to severe active Crohn’s Disease. NCT03677648
Study 3: RSJ10303 a Phase II Study in patients with moderate to severe Atopic Dermatitis NCT04162899
Study 4: RSJ10521 a Phase II Study in Patients with moderate to severe Alopecia Areata NCT04346316